Meningococcal conjugate vaccination
View Patent ↗Conjugated meningococcal capsular saccharides will be introduced into immunization schedules in the near future, but the phenomenon of “carrier suppression” must first be addressed, particularly where multiple conjugates are to be used. In the invention, tetanus toxoid is used as the carrier protein, even where multiple meningococcal conjugates are administered at the same time and where a patient has previously been exposed to the carrier protein, either in the form of a previous immunogen (e.g. in a DTP vaccine) or as a previous carrier protein (e.g. in a Hib or pneumococcal conjugate vaccine). The invention provides a method for immunizing a patient, comprising administering multiple conjugates of meningococcal capsular saccharides, wherein each conjugate comprises a tetanus toxoid carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunized with a tetanus toxoid.
1. A method for immunising a human patient against a disease caused by Neisseria meningitidis , comprising the step of administering to the human patient a composition that comprises at least two of: (a) a conjugate of (i) the capsular saccharide of serogroup A N. meningitidis and (ii) a tetanus toxoid carrier; (b) a conjugate of (i) the capsular saccharide of serogroup C N. meningitidis and (ii) a tetanus toxoid carrier; (c) a conjugate of (i) the capsular saccharide of serogroup W135 N. meningitidis and (ii) a tetanus toxoid carrier; and (d) a conjugate of (i) the capsular saccharide of serogroup Y N. meningitidis and (ii) a tetanus toxoid carrier, wherein the patient has been pre-immunised with (x) a non-conjugated tetanus toxoid antigen and/or (y) a conjugate of (i) a capsular saccharide of an organism other than N. meningitidis and (ii) a tetanus toxoid carrier, wherein the patient was pre-immunised at least six months before the method.
2. The method of claim 1 , wherein the composition comprises all four of (a), (b), (c) and (d).
3. The method of claim 1 , wherein the patient has been pre-immunised with a vaccine comprising (x).
4. The method of claim 1 , wherein the patient has been pre-immunised with a vaccine comprising (y), wherein the organism other than N. meningitidis is Haemophilus influenzae.
5. The method of claim 1 , wherein the patient has been pre-immunised with a vaccine comprising at least one pneumococcal conjugate.
6. The method claim 1 , wherein the patient was pre-immunised at least 8 years before the method.
7. The method of claim 1 , wherein the pre-immunisation took place within 1 year of the patient's birth.
8. The method of claim 1 , wherein the saccharides in the meningococcal conjugates (a) to (d) are shorter than the native capsular saccharides seen in meningococcus.
9. The method of claim 1 , wherein the meningococcal conjugates comprise an adipic acid linker conjugating the tetanus toxoid carriers to the respective capsular saccharides of (a), (b), (c), and/or (d).
10. The method of claim 9 , wherein the composition comprises no more than 60 μg of tetanus toxoid carrier.
11. The method of claim 1 , wherein the composition further comprises a conjugated capsular saccharide from Streptococcus pneumoniae.
12. The method of claim 1 , wherein the composition further comprises a conjugated capsular saccharide from Haemophilus influenzae type B.
13. The method of claim 1 , wherein the composition further comprises a protein antigen from serogroup B of Neisseria meningitidis.
14. The method of claim 1 , wherein the composition includes an aluminium hydroxide adjuvant and/or an aluminium phosphate adjuvant.
15. The method of claim 1 , wherein the disease caused by Neisseria meningitidis is meningococcal meningitis.
16. The method of claim 2 , wherein the patient has been pre-immunised with a vaccine comprising (x).
17. The method of claim 2 , wherein the patient has been pre-immunised with a vaccine comprising (y), wherein the organism other than N. meningitidis is Haemophilus influenzae.
18. The method of claim 2 , wherein the patient has been pre-immunised with a vaccine comprising at least one pneumococcal conjugate.
19. The method of claim 2 , wherein the patient was pre-immunised at least 8 years before the method.
20. The method of claim 2 , wherein the pre-immunisation took place within 1 year of the patient's birth.
21. The method of claim 2 , wherein the saccharides in the meningococcal conjugates (a) to (d) are shorter than the native capsular saccharides seen in meningococcus.
22. The method of claim 2 , wherein the meningococcal conjugates comprise an adipic acid linker conjugating the tetanus toxoid carriers to the respective capsular saccharides of (a), (b), (c), and/or (d).
23. The method of claim 22 , wherein the composition comprises no more than 60 μg of tetanus toxoid carrier.
24. The method of claim 2 , wherein the composition further comprises a conjugated capsular saccharide from Streptococcus pneumoniae.
25. The method of claim 2 , wherein the composition further comprises a conjugated capsular saccharide from Haemophilus influenzae type B.
26. The method of claim 2 , wherein the composition further comprises a protein antigen from serogroup B of Neisseria meningitidis.
27. The method of claim 2 , wherein the composition includes an aluminium hydroxide adjuvant and/or an aluminium phosphate adjuvant.
28. The method of claim 2 , wherein the disease caused by Neisseria meningitidis is meningococcal meningitis.